These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36806515)

  • 1. Meeting Report: 2022 Muscular Dystrophy Association Summit on 'Safety and Challenges in Gene Transfer Therapy'.
    Lek A; Atas E; Hesterlee SE; Byrne BJ; Bönnemann CG
    J Neuromuscul Dis; 2023; 10(3):327-336. PubMed ID: 36806515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges for gene therapy for muscular dystrophy.
    Mendell JR; Clark KR
    Curr Neurol Neurosci Rep; 2006 Jan; 6(1):47-56. PubMed ID: 16469271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AAV-based gene therapies for the muscular dystrophies.
    Crudele JM; Chamberlain JS
    Hum Mol Genet; 2019 Oct; 28(R1):R102-R107. PubMed ID: 31238336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene therapy for muscle diseases.
    Coovert DD; Burghes AH
    Curr Opin Neurol; 1994 Oct; 7(5):463-70. PubMed ID: 7804468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The progress of AAV-mediated gene therapy in neuromuscular disorders.
    Aguti S; Malerba A; Zhou H
    Expert Opin Biol Ther; 2018 Jun; 18(6):681-693. PubMed ID: 29781327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene therapy for muscular dystrophy: lessons learned and path forward.
    Mendell JR; Rodino-Klapac L; Sahenk Z; Malik V; Kaspar BK; Walker CM; Clark KR
    Neurosci Lett; 2012 Oct; 527(2):90-9. PubMed ID: 22609847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome engineering: a new approach to gene therapy for neuromuscular disorders.
    Nelson CE; Robinson-Hamm JN; Gersbach CA
    Nat Rev Neurol; 2017 Nov; 13(11):647-661. PubMed ID: 28960187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress in gene therapy of dystrophic heart disease.
    Lai Y; Duan D
    Gene Ther; 2012 Jun; 19(6):678-85. PubMed ID: 22318092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AAV-directed muscular dystrophy gene therapy.
    Tang Y; Cummins J; Huard J; Wang B
    Expert Opin Biol Ther; 2010 Mar; 10(3):395-408. PubMed ID: 20132060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies.
    Cordier L; Gao GP; Hack AA; McNally EM; Wilson JM; Chirmule N; Sweeney HL
    Hum Gene Ther; 2001 Jan; 12(2):205-15. PubMed ID: 11177557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene therapy for muscular dystrophy: moving the field forward.
    Al-Zaidy S; Rodino-Klapac L; Mendell JR
    Pediatr Neurol; 2014 Nov; 51(5):607-18. PubMed ID: 25439576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic gene transfer to skeletal muscle using reengineered AAV vectors.
    Phillips JL; Hegge J; Wolff JA; Samulski RJ; Asokan A
    Methods Mol Biol; 2011; 709():141-51. PubMed ID: 21194026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene transfer to muscle.
    Dickson G
    Biochem Soc Trans; 1996 May; 24(2):514-9. PubMed ID: 8736795
    [No Abstract]   [Full Text] [Related]  

  • 14. Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy.
    Duan D
    Mol Ther; 2018 Oct; 26(10):2337-2356. PubMed ID: 30093306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models.
    Song Y; Morales L; Malik AS; Mead AF; Greer CD; Mitchell MA; Petrov MT; Su LT; Choi ME; Rosenblum ST; Lu X; VanBelzen DJ; Krishnankutty RK; Balzer FJ; Loro E; French R; Propert KJ; Zhou S; Kozyak BW; Nghiem PP; Khurana TS; Kornegay JN; Stedman HH
    Nat Med; 2019 Oct; 25(10):1505-1511. PubMed ID: 31591596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of T-Cell Infiltration and Programmed Death Ligand 2 Expression by Adeno-Associated Virus in Rhesus Macaque Skeletal Muscle and Modulation by Prednisone.
    Cramer ML; Shao G; Rodino-Klapac LR; Chicoine LG; Martin PT
    Hum Gene Ther; 2017 Jun; 28(6):493-509. PubMed ID: 28345428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical development on the frontier: gene therapy for duchenne muscular dystrophy.
    Asher DR; Thapa K; Dharia SD; Khan N; Potter RA; Rodino-Klapac LR; Mendell JR
    Expert Opin Biol Ther; 2020 Mar; 20(3):263-274. PubMed ID: 32031420
    [No Abstract]   [Full Text] [Related]  

  • 18. Genetic treatments in muscular dystrophies.
    Muntoni F; Wells D
    Curr Opin Neurol; 2007 Oct; 20(5):590-4. PubMed ID: 17885450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of an ultrasound-mediated nucleic acid delivery system for treating muscular dystrophies].
    Negishi Y; Hamano N; Shiono H; Akiyama S; Endo-Takahashi Y; Suzuki R; Maruyama K; Aramaki Y
    Yakugaku Zasshi; 2012; 132(12):1383-8. PubMed ID: 23208045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Directed evolution of adeno-associated virus (AAV) as vector for muscle gene therapy.
    Yang L; Li J; Xiao X
    Methods Mol Biol; 2011; 709():127-39. PubMed ID: 21194025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.